𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimizing thiopurine therapy in inflammatory bowel disease

✍ Scribed by Jean-Baptiste Chevaux; Laurent Peyrin-Biroulet; Miles P. Sparrow

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
113 KB
Volume
17
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

✦ Synopsis

Despite recent advances, the therapeutic armamentarium for inflammatory bowel disease (IBD) is still limited. In addition, a step-up approach is recommended for most IBD patients. Thus, optimizing each medical therapy before switching to another drug class is the rule in clinical practice. Conventional therapies for IBD have not received the same amount of attention as biologic therapies over the last decade. However, due to their efficacy, safety, and low cost the thiopurine drugs azathioprine and 6-mercaptopurine remain the backbone of therapy for IBD. Pharmacogenomic advances and increased knowledge of their metabolism are allowing dosage optimization. Herein, after describing the pharmacogenetics and pharmacokinetics of thiopurines, we will discuss how to optimize thiopurine therapy. We will then underscore the need to take into account safety issues when optimizing thiopurine treatment.

πŸ“œ SIMILAR VOLUMES

Initial clinical experience with allopur
Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease
✍ Riad M. Rahhal; Warren P. Bishop πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 95 KB πŸ‘ 1 views

Background: Thiopurines are a mainstay of immunomodulator therapy in inflammatory bowel disease (IBD). Despite their efficacy, some patients may have a poor response due to inability to achieve adequate levels of the active metabolite, 6-thioguanine (6-TGN). Others experience hepatotoxicity, which c

Thiopurine therapy in inflammatory bowel
Thiopurine therapy in inflammatory bowel disease patients: Analyses of two 8-year intercept cohorts
✍ B. Jharap; M.L. Seinen; N.K.H. de Boer; J.R. van Ginkel; R.K. Linskens; J.C. Kne πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 185 KB πŸ‘ 2 views

Background: Thiopurines have proven efficacy in long-term maintenance therapy of inflammatory bowel disease (IBD). Limited data are available with regard to factors predicting effectiveness and failure of long-term thiopurine use in IBD patients. ## Methods: The data in this retrospective study a

Normal response to vaccines in inflammat
Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines
✍ Iris Dotan; Lael Werner; Sharon Vigodman; Shradha Agarwal; Jorge Pfeffer; Noya H πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 199 KB πŸ‘ 2 views

Background: Thiopurines are considered immunosuppressive agents and may be associated with an increased risk for infections. However, few inflammatory bowel disease (IBD) patients are appropriately vaccinated, and data on their ability to mount an immune response are vague. We evaluated the effects

Smoking status and response to thiopurin
Smoking status and response to thiopurines in steroid-dependent inflammatory bowel disease
✍ Eugeni DomΓ¨nech; SΓ­lvia CarriΓ³n; Esther Garcia-Planella; MΓ­riam MaΓ±osa; Jordi Go πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 99 KB πŸ‘ 2 views

## Background: The influence of smoking on inflammatory bowel disease (IBD) susceptibility and on its clinical course is well known, but not its impact on drug efficacy. The aim of this study was to evaluate the response to thiopurines in patients with steroid-dependent IBD according to their smok

Mycophenolate mofetil therapy for refrac
Mycophenolate mofetil therapy for refractory inflammatory bowel disease
✍ S. Palaniappan; A. C. Ford; D. Greer; S. M. Everett; D. M. Chalmers; A. T. R. Ax πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 78 KB

Background: Mycophenolate mofetil (MMF) is an immunomodulatory drug, and its use in inflammatory bowel disease has previously been reported. The aim of this study was to review the Leeds Colitis Clinic experience of the safety and efficacy of MMF in treating patients with refractory Crohn's disease